

Pfizer Inc. Revenues -- Recast to Reflect 2019 Commercial Operating Structure**
Full Year 2018 and 2017
Unaudited
(millions of dollars)
Year-To-Date

TOTAL REVENUES	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)			
	2018		2017		2018		2017		2018		2017		2018		2017		2018		2017		2018		2017	
			Reported	% of Change			Reported	% of Change			Reported	% of Change			Reported	% of Change			Reported	% of Change			Reported	% of Change
TOTAL REVENUES	\$ 53,647	\$ 52,546	2%	2%	\$ 25,329	\$ 26,026	(3)%	\$ 28,318	\$ 26,519	7%	6%	\$ 9,116	\$ 8,508	7%	2%	\$ 6,551	\$ 6,612	(1)%	(2)%	\$ 12,651	\$ 11,399	11%	13%	
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(a)	\$ 37,558	\$ 35,530	6%	5%	\$ 18,243	\$ 17,961	2%	\$ 19,315	\$ 17,569	10%	9%	\$ 7,540	\$ 6,747	12%	6%	\$ 4,080	\$ 4,005	2%	1%	\$ 7,695	\$ 6,817	13%	16%	
Internal Medicine^(a)	\$ 8,869	\$ 8,229	8%	7%	\$ 4,542	\$ 4,321	5%	\$ 4,327	\$ 3,908	11%	10%	\$ 1,707	\$ 1,391	23%	17%	\$ 1,312	\$ 1,333	(2)%	(3)%	\$ 1,308	\$ 1,184	11%	16%	
Eliquis alliance revenues and direct sales	3,434	2,523	36%	35%	1,849	1,418	30%	1,585	1,105	43%	40%	947	630	50%	44%	333	275	21%	20%	304	200	52%	56%	
Chantix/Champix	1,085	997	9%	8%	838	742	13%	247	255	(3)%	(5)%	83	78	7%	2%	111	134	(17)%	(18)%	52	43	22%	26%	
Premarin family	832	977	(15)%	(15)%	783	921	(15)%	49	56	(12)%	(12)%	2	2	(20)%	(23)%	23	27	(12)%	(12)%	24	27	(12)%	(11)%	
BMP2	279	261	7%	7%	278	261	6%	1	—	—	—	—	—	—	—	—	—	—	—	1	—	—	—	
Tolviz	271	257	5%	4%	87	85	3%	183	173	6%	4%	71	67	6%	1%	101	95	6%	5%	11	11	4%	14%	
Pristiq	206	303	(32)%	(32)%	71	133	(47)%	135	170	(20)%	(20)%	32	28	15%	9%	44	69	(37)%	(37)%	59	73	(18)%	(15)%	
All other Internal Medicine	2,763	2,910	(5)%	(5)%	636	761	(16)%	2,127	2,149	(1)%	(1)%	571	585	(2)%	(7)%	700	733	(5)%	(6)%	857	831	3%	9%	
Vaccines	\$ 6,332	\$ 6,001	6%	5%	\$ 3,469	\$ 3,422	1%	\$ 2,863	\$ 2,580	11%	11%	\$ 974	\$ 893	9%	4%	\$ 420	\$ 445	(5)%	(7)%	\$ 1,469	\$ 1,242	18%	22%	
Prevnar 13/Prevarar 13	5,802	5,601	4%	4%	3,360	3,334	1%	2,443	2,268	8%	8%	655	643	2%	(2)%	402	432	(7)%	(8)%	1,386	1,193	16%	20%	
FSME/IMMUN-Tico/Vac	184	134	37%	28%	—	—	—	184	134	37%	28%	158	116	37%	29%	—	—	—	—	25	18	37%	24%	
Trumenba	116	88	31%	31%	109	88	24%	7	—	—	—	6	—	—	—	—	—	—	1	—	—	—		
All other Vaccines	230	177	29%	29%	—	—	—	230	177	29%	29%	155	134	15%	10%	18	13	40%	44%	57	30	88%	—	
Oncology^(a)	\$ 7,471	\$ 6,304	19%	18%	\$ 4,657	\$ 4,392	6%	\$ 2,814	\$ 1,912	47%	46%	\$ 1,436	\$ 848	69%	61%	\$ 573	\$ 355	61%	59%	\$ 806	\$ 708	14%	21%	
Ibrance	4,118	3,126	32%	32%	2,922	2,825	3%	1,196	300	—	—	725	124	—	—	245	34	—	—	226	143	58%	84%	
Sutent	1,049	1,081	(3)%	(4)%	357	374	(4)%	692	707	(2)%	(3)%	323	323	—	(5)%	119	121	(2)%	(4)%	250	262	(5)%	(1)%	
Xtandi alliance revenues	699	590	18%	18%	699	590	18%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Xalkori	524	594	(12)%	(14)%	158	223	(29)%	366	371	(1)%	(4)%	154	175	(12)%	(18)%	58	56	4%	1%	154	139	11%	11%	
Inlyta	298	339	(12)%	(12)%	119	126	(5)%	178	213	(16)%	(16)%	48	70	(31)%	(35)%	77	86	(10)%	(12)%	53	57	(8)%	(1)%	
Bosulfif	296	233	27%	26%	196	156	26%	99	77	28%	25%	52	40	29%	23%	39	32	24%	22%	8	5	56%	55%	
All other Oncology	488	340	43%	41%	205	98	—	283	243	17%	13%	134	116	16%	9%	34	26	31%	30%	115	101	14%	13%	
Inflammation & Immunology (I&I)^(a)	\$ 4,720	\$ 4,386	8%	7%	\$ 1,816	\$ 1,384	31%	\$ 2,904	\$ 3,002	(3)%	(4)%	\$ 1,574	\$ 1,692	(7)%	(12)%	\$ 577	\$ 559	3%	2%	\$ 753	\$ 750	—	9%	
Enbrel (Outside the U.S. and Canada)	2,112	2,452	(14)%	(14)%	—	—	—	2,112	2,452	(14)%	(14)%	1,152	1,410	(18)%	(23)%	358	395	(10)%	(10)%	603	647	(7)%	1%	
Xeljanz	1,774	1,345	32%	33%	1,394	1,133	23%	380	212	79%	84%	121	39	—	—	148	97	52%	52%	110	76	45%	64%	
Inflectra/Remsima	642	419	53%	50%	259	118	—	383	301	27%	23%	319	261	22%	16%	24	13	91%	92%	40	27	49%	50%	
Eucrisa	147	67	—	—	147	67	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
All other I&I	45	103	(57)%	(57)%	16	66	(75)%	28	37	(23)%	(24)%	(18)	(18)	(1)%	3%	46	54	(15)%	(16)%	—	—	—	—	
Rare Disease	\$ 2,211	\$ 2,240	(1)%	(2)%	\$ 652	\$ 632	3%	\$ 1,560	\$ 1,608	(3)%	(5)%	\$ 835	\$ 892	(6)%	(11)%	\$ 368	\$ 388	(5)%	(6)%	\$ 357	\$ 328	9%	16%	
Genotropin	568	532	5%	4%	130	98	33%	428	434	(1)%	(3)%	179	177	2%	(3)%	156	160	(2)%	(4)%	92	97	(5)%	1%	
BeneFIX	564	604	(8)%	(9)%	245	253	(3)%	309	351	(12)%	(13)%	153	192	(20)%	(25)%	82	99	(17)%	(19)%	74	60	24%	32%	
Refacto AF/Xyntha	514	551	(7)%	(8)%	109	114	(4)%	404	438	(8)%	(9)%	245	291	(16)%	(20)%	48	53	(8)%	(9)%	111	94	18%	24%	
Somavert	267	254	5%	3%	103	95	8%	164	158	4%	—	130	125	4%	(1)%	20	18	8%	7%	14	15	(7)%	1%	
All other Rare Disease	318	300	6%	6%	64	72	(10)%	254	228	11%	11%	127	108	17%	11%	62	57	8%	6%	66	63	5%	15%	
Hospital^(a)	\$ 7,955	\$ 8,369	(5)%	(6)%	\$ 3,107	\$ 3,810	(18)%	\$ 4,848	\$ 4,559	6%	5%	\$ 1,015	\$ 1,031	(1)%	(6)%	\$ 830	\$ 925	(10)%	(11)%	\$ 3,002	\$ 2,604	15%	15%	
Sulperazon	613	471	30%	27%	—	—	—	613	471	30%	27%	—	—	—	—	10	12	(18)%	(20)%	603	460	31%	28%	
Medrol ^(a)	493	540	(9)%	(10)%	266	318	(17)%	227	221	3%	1%	74	73	2%	(4)%	26	26	—	—	127	123	4%	3%	
Vlend ^(a)	392	421	(7)%	(7)%	10	13	(24)%	382	407	(6)%	(6)%	36	57	(37)%	(41)%	80	104	(23)%	(25)%	267	246	8%	9%	
EpiPen	303	290	4%	4%	242	221	9%	62	70	(11)%	(12)%	—	—	—	—	62	70	(11)%	(12)%	—	—	—	—	
Fragmin	293	306	(4)%	(4)%	14	20	(31)%	279	286	(2)%	(5)%	143	148	(4)%	(8)%	75	79	(5)%	(6)%	61	59	4%	2%	
Zithromax ^(a)	292	272	8%	5%	5	3	—	287	269	7%	4%	49	46	6%	—	38	47	(19)%	(21)%	200	176	14%	11%	
Tygacil	249	260	(5)%	(6)%	25	45	(44)%	223	215	4%	2%	66	78	(15)%	(21)%	6	6	(10)%	(13)%	151	131	16%	16%	
Zyvox ^(a)	236	281	(16)%	(18)%	(3)	15	(122)%	239	266	(10)%	(12)%	15	28	(47)%	(51)%	55	65	(15)%	(17)%	169	172	(2)%	(4)%	
Zosyn/Tazocin	230	195	18%	19%	151	160	(6)%	79	35	—	—	5	2	—	—	5	2	—	—	70	31	—	—	
Precedex	213	243	(12)%	(12)%	97	140	(31)%	116	104	12%	12%	—	—	—	—	68	57	20%	19%	48	47	3%	4%	
Pfizer CentreOne ^(a)	755	706	7%	6%	409	537	(24)%	345	169	—	—	138	109	26%	26%	15	18	(14)%	(14)%	192	43	—	—	
All other Anti-infectives	1,264	1,445	(13)%	(13)%	300	513	(42)%	964	932	3%	3%	277	242	15%	8%	109	115	(5)%	(6)%	578	575	—	3%	
All other Hospital ^(a)	2,623	2,939	(11)%	(11)%	1,591	1,824	(13)%	1,032	1,115	(7)%	(9)%	213	248	(14)%	(19)%	282	325	(13)%	(13)%	536	542	(1)%	(2)%	
UPJOHN^(a)	\$ 12,484	\$ 13,447	(7)%	(8)%	\$ 5,209	\$ 6,150	(15)%	\$ 7,275	\$ 7,297	—	(2)%	\$ 1,102	\$ 1,330	(17)%	(21)%	\$ 2,140	\$ 2,286	(6)%	(8)%	\$ 4,031	\$ 3,681	10%	9%	
Lyrca	4,970																							

Pfizer Inc. Revenues -- Recast to Reflect 2019 Commercial Operating Structure**
First Quarter 2018 and 2017
Unaudited
(millions of dollars)
Quarter-To-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)			
	2018		2017		2018		2017		2018		2017		2018		2017		2018		2017		2018		2017	
	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change
TOTAL REVENUES	\$ 12,906	\$ 12,779	1%	(2)%	\$ 6,275	\$ 6,637	(5)%	\$ 6,631	\$ 6,142	8%	1%	\$ 2,092	\$ 2,021	4%	(8)%	\$ 1,461	\$ 1,554	(6)%	(10)%	\$ 3,078	\$ 2,567	20%	15%	
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	\$ 8,881	\$ 8,538	4%	1%	\$ 4,388	\$ 4,505	(3)%	\$ 4,493	\$ 4,033	11%	4%	\$ 1,721	\$ 1,590	8%	(4)%	\$ 911	\$ 954	(4)%	(8)%	\$ 1,861	\$ 1,489	25%	21%	
Internal Medicine^(c)	\$ 2,071	\$ 1,960	6%	2%	\$ 1,087	\$ 1,075	1%	\$ 984	\$ 884	11%	4%	\$ 377	\$ 305	24%	10%	\$ 292	\$ 314	(7)%	(11)%	\$ 315	\$ 266	18%	15%	
Eliquis alliance revenues and direct sales	765	564	35%	30%	435	342	27%	330	223	48%	35%	191	124	54%	36%	68	61	10%	6%	71	37	91%	79%	
Chantix/Champix	251	239	5%	3%	188	179	5%	64	61	5%	(2)%	21	19	14%	1%	28	32	(14)%	(19)%	14	9	53%	51%	
Premarin family	191	228	(16)%	(16)%	180	214	(16)%	11	14	(19)%	(24)%	—	1	(38)%	(44)%	6	7	(12)%	(15)%	5	6	(26)%	(30)%	
BMP2	73	62	18%	18%	73	62	18%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Toviaz	60	63	(5)%	(9)%	18	24	(25)%	42	39	8%	1%	17	14	18%	5%	22	21	2%	(2)%	3	3	4%	1%	
Pristiq	53	116	(54)%	(56)%	21	74	(71)%	32	41	(24)%	(28)%	7	6	28%	13%	11	16	(34)%	(37)%	14	19	(30)%	(31)%	
All other Internal Medicine	677	688	(2)%	(5)%	171	180	(5)%	506	507	—	(5)%	140	141	(1)%	(12)%	158	175	(10)%	(13)%	208	191	9%	6%	
Vaccines	\$ 1,463	\$ 1,465	—	(3)%	\$ 837	\$ 951	(12)%	\$ 626	\$ 515	22%	15%	\$ 198	\$ 191	4%	(8)%	\$ 106	\$ 107	(1)%	(6)%	\$ 322	\$ 216	49%	45%	
Prenar 13/Prenar 13	1,380	1,392	(1)%	(3)%	826	938	(12)%	555	454	22%	16%	141	139	2%	(10)%	103	106	(3)%	(7)%	310	210	48%	45%	
All other Vaccines	83	73	13%	3%	11	12	(7)%	71	61	18%	5%	57	52	8%	(5)%	3	1	*	96%	12	7	75%	63%	
Oncology^(d)	\$ 1,760	\$ 1,406	25%	22%	\$ 1,135	\$ 955	19%	\$ 625	\$ 451	38%	28%	\$ 300	\$ 216	39%	22%	\$ 113	\$ 81	41%	35%	\$ 212	\$ 154	37%	34%	
Ibrance	933	679	37%	35%	726	608	19%	207	71	*	*	116	43	*	*	41	5	*	*	49	23	*	*	
Sutent	262	250	5%	(1)%	88	85	3%	174	165	6%	(2)%	80	75	6%	(6)%	27	29	(7)%	(11)%	67	60	11%	6%	
Xtandi alliance revenues	159	131	21%	21%	159	131	21%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Xalkori	153	142	8%	2%	42	57	(26)%	110	85	31%	21%	46	40	15%	2%	15	13	15%	9%	50	32	56%	49%	
Inlyta	74	85	(13)%	(16)%	28	30	(9)%	46	54	(15)%	(20)%	13	19	(31)%	(38)%	17	21	(19)%	(21)%	15	14	10%	7%	
Bosulfif	60	47	29%	26%	41	32	26%	20	14	36%	25%	10	7	38%	22%	8	6	20%	16%	2	1	*	*	
All other Oncology	119	73	64%	56%	51	10	*	68	62	9%	(1)%	34	31	10%	(3)%	5	6	(21)%	(24)%	28	25	15%	8%	
Inflammation & Immunology (I&I)^(e)	\$ 1,013	\$ 949	7%	1%	\$ 338	\$ 251	35%	\$ 675	\$ 698	(3)%	(11)%	\$ 280	\$ 405	(6)%	(17)%	\$ 133	\$ 131	2%	(2)%	\$ 162	\$ 162	—	(2)%	
Enbrel (Outside the U.S. and Canada)	506	588	(14)%	(21)%	—	—	—	506	588	(14)%	(21)%	290	348	(17)%	(27)%	89	95	(6)%	(9)%	126	145	(13)%	(14)%	
Xeljanz	326	250	30%	29%	253	212	19%	72	38	89%	82%	19	5	*	*	29	20	44%	38%	24	13	83%	87%	
Inflectra/Remsima	145	78	86%	73%	55	17	*	90	61	48%	32%	75	54	39%	23%	4	3	47%	40%	11	4	*	*	
Eucrisa	26	9	*	*	26	9	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
All other I&I	11	24	(54)%	(53)%	4	13	(66)%	6	11	(39)%	(38)%	(5)	(2)	*	(92)%	11	13	(12)%	(15)%	—	—	—	—	
Rare Disease	\$ 549	\$ 507	8%	2%	\$ 172	\$ 126	36%	\$ 377	\$ 381	(1)%	(9)%	\$ 207	\$ 208	—	(12)%	\$ 87	\$ 94	(8)%	(12)%	\$ 83	\$ 78	7%	4%	
BeneFIX	147	149	(2)%	(6)%	68	59	16%	79	91	(13)%	(20)%	40	48	(16)%	(26)%	21	27	(22)%	(27)%	17	15	12%	10%	
Genotropin	132	104	28%	21%	31	4	*	101	99	2%	(5)%	44	40	8%	(4)%	35	37	(6)%	(10)%	22	21	3%	—	
Refacto AF/Xyntha	130	130	—	(7)%	30	26	14%	100	104	(4)%	(12)%	64	68	(6)%	(17)%	14	13	6%	1%	23	23	(2)%	(4)%	
Somavert	63	56	12%	5%	24	20	22%	39	36	6%	(5)%	31	29	7%	(6)%	4	4	12%	7%	3	4	(1)%	(5)%	
All other Rare Disease	76	67	13%	7%	18	17	7%	58	50	16%	7%	28	23	23%	8%	12	13	(5)%	(9)%	18	14	23%	20%	
Hospital^(f)	\$ 2,026	\$ 2,252	(10)%	(13)%	\$ 820	\$ 1,147	(29)%	\$ 1,206	\$ 1,105	9%	3%	\$ 259	\$ 265	(2)%	(13)%	\$ 179	\$ 227	(21)%	(24)%	\$ 768	\$ 612	25%	19%	
Suplerazon	168	122	38%	29%	—	—	—	168	122	38%	29%	—	—	—	—	2	3	(19)%	(22)%	166	119	39%	31%	
Medrol ^(g)	136	134	1%	(1)%	83	82	2%	52	52	1%	(7)%	18	18	3%	(9)%	5	6	(12)%	(16)%	28	28	2%	(3)%	
Vlend ^(g)	98	107	(9)%	(13)%	2	5	(57)%	96	102	(6)%	(11)%	10	18	(43)%	(50)%	20	26	(23)%	(26)%	66	59	12%	7%	
Zithromax ^(g)	90	79	14%	7%	1	1	(16)%	89	78	15%	8%	16	16	4%	(9)%	10	14	(28)%	(31)%	63	49	30%	23%	
Fragmin	70	71	(1)%	(9)%	4	4	—	66	67	(1)%	(10)%	37	35	3%	(7)%	18	20	(14)%	(12)%	11	12	(7)%	(16)%	
Zyvox ^(g)	68	77	(11)%	(16)%	6	9	(40)%	63	68	(7)%	(13)%	6	10	(40)%	(47)%	12	16	(25)%	(28)%	45	43	6%	1%	
Tyagcil	63	74	(15)%	(21)%	7	21	(68)%	56	53	5%	(2)%	19	17	15%	1%	1	2	(8)%	(15)%	35	35	1%	(4)%	
Zosyn/Tazocin	61	38	64%	62%	43	34	25%	19	3	*	*	1	—	*	*	2	—	*	*	16	3	*	*	
Precedex	55	64	(15)%	(16)%	27	38	(29)%	28	26	6%	2%	—	—	—	—	16	16	5%	—	11	11	8%	5%	
EpiPen	52	81	(36)%	(36)%	45	69	(35)%	8	12	(36)%	(39)%	—	—	—	—	8	12	(36)%	(39)%	—	—	—	—	
Pfizer CentreOne ^(h)	171	182	(6)%	(7)%	96	137	(30)%	75	45	69%	(39)%	24	31	(22)%	(24)%	2	4	(38)%	(39)%	49	10	*	*	
All other Anti-infectives	340	335	1%	(3)%	101	136	(26)%	239	199	20%	13%	67	55	21%	7%	24	29	(17)%	(20)%	148	114	29%	25%	
All other Hospital ^(f)	653	887	(26)%	(28)%	405	610	(34)%	248	277	(11)%	(16)%	61	67	(9)%	(20)%	58	81	(28)%	(31)%	129	130	(1)%	(5)%	
UPJOHN⁽ⁱ⁾	\$ 3,120	\$ 3,296	(5)%	(8)%	\$ 1,408	\$ 1,608	(12)%	\$ 1,712	\$ 1,688	1%	(5)%	\$ 266	\$ 335	(21)%	(30)%	\$ 465	\$ 514	(10)%	(14)%	\$ 981	\$ 839	17%	11%	
Lyrica	1,213	1,271	(5)%	(6)%	907	891	2%	307	380	(19)%	(24)%	63	117	(46)%	(52)%	169	188	(10)%	(14)%	74	75	(1)%	(5)%	
Lipitor	511	404	27%	19%	29	30	(6)%	483	374	29%	21%	44	42	5%	(8)%	46	53	(13)%	(21)%	393	279	41%	33%	
Norvasc	256	228	12%	6%	9	10	(5)%	246	218	13%	7%	17	17	3%	(10)%	45	50	(11)%	(15)%	184	151	22%	16%	
Viagra	187	339	(45)%	(46)%	88	242	(63)%	99	97	2%	(4)%	9	12	(20)%	(29)%	16	17	(5)%	(9)%	73	69	7%	1%	
Celebrex	145	175	(17)%	(21)%	16	30	(49)%	129	144	(11)%	(15)%													

Pfizer Inc. Revenues -- Recast to Reflect 2019 Commercial Operating Structure**
Second Quarter 2018 and 2017
 Unaudited
 (millions of dollars)
 Quarter-To-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(b)				DEVELOPED EUROPE ^{(b)(c)}				DEVELOPED REST OF WORLD ^{(b)(c)}				EMERGING MARKETS ^(b)									
	2018	2017	% of Change		2018	2017	% of Change		2018	2017	% of Change		2018	2017	% of Change		2018	2017	% of Change		2018	2017	2018	2017	Reported	14%	Operational	12%		
			Reported	Operational			Reported	Operational			Reported	Operational			Reported	Operational			Reported	Operational									Reported	Operational
TOTAL REVENUES	\$ 13,466	\$ 12,896	4%	2%	\$ 6,225	\$ 6,345	(2)%		\$ 7,242	\$ 6,551	11%	5%	\$ 2,334	\$ 2,124	10%	(2)%	\$ 1,694	\$ 1,611	5%	1%	\$ 3,214	\$ 2,815	14%	14%	12%	12%				
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	\$ 9,434	\$ 8,694	9%	6%	\$ 4,509	\$ 4,371	3%		\$ 4,925	\$ 4,323	14%	8%	\$ 1,921	\$ 1,679	14%	3%	\$ 1,058	\$ 981	8%	4%	\$ 1,945	\$ 1,663	17%	17%	16%	16%				
Internal Medicine ^(d)	\$ 2,276	\$ 2,005	14%	11%	\$ 1,161	\$ 1,059	10%		\$ 1,115	\$ 946	18%	12%	\$ 444	\$ 314	41%	27%	\$ 347	\$ 334	4%	—	\$ 324	\$ 298	9%	9%	11%					
Eliquis alliance revenues and direct sales	889	605	47%	42%	482	347	39%		407	258	58%	46%	247	143	73%	56%	87	68	28%	23%	73	47	55%	52%						
Chantix/Champix	277	248	12%	11%	217	184	18%		60	64	(6)%	(11)%	20	18	11%	(1)%	30	36	(16)%	(20)%	10	10	3%	4%						
Premarin family	210	245	(14)%	(14)%	197	232	(15)%		13	13	(4)%	(7)%	1	1	—	(10)%	5	6	(17)%	(20)%	7	6	9%	6%						
BMP2	80	57	40%	40%	80	56	43%		—	1	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—					
Tolvaz	70	62	13%	8%	21	20	9%		49	43	14%	8%	18	16	12%	—	28	24	14%	10%	3	2	35%	39%						
Pristiq	51	46	10%	8%	15	5	—		36	41	(12)%	(14)%	8	7	23%	9%	11	16	(33)%	(36)%	16	18	(6)%	(3)%						
All other Internal Medicine	700	743	(6)%	(8)%	149	216	(31)%		550	527	4%	2%	149	128	16%	5%	186	163	2%	(2)%	215	215	—	—						
Vaccines	\$ 1,400	\$ 1,270	10%	8%	\$ 702	\$ 670	5%		\$ 698	\$ 600	16%	12%	\$ 239	\$ 205	17%	5%	\$ 109	\$ 99	10%	6%	\$ 350	\$ 296	18%	18%						
Prevnar 13/Prevnar 13	1,250	1,154	8%	7%	682	645	6%		568	510	11%	8%	141	138	2%	(8)%	107	96	11%	7%	320	276	16%	17%						
FSME/IMMUN-TicoVac	73	50	46%	32%	—	—	—		73	50	46%	32%	59	40	49%	36%	—	—	—	—	14	10	36%	19%						
All other Vaccines	77	66	17%	10%	21	25	(18)%		56	41	39%	28%	39	28	41%	25%	2	2	(26)%	(28)%	16	10	50%	49%						
Oncology^(b)	\$ 1,888	\$ 1,647	15%	12%	\$ 1,178	\$ 1,122	5%		\$ 710	\$ 525	35%	27%	\$ 357	\$ 269	33%	19%	\$ 145	\$ 88	65%	59%	\$ 208	\$ 169	23%	23%	24%					
Ibrance	1,027	853	20%	19%	744	727	2%		283	126	—	(1)	173	86	—	79%	58	7	—	—	52	33	58%	77%						
Sutent	275	279	(1)%	(5)%	94	106	(11)%		181	273	5%	(1)%	81	78	4%	(8)%	32	30	5%	1%	69	65	6%	5%						
Xtandi alliance revenues	171	141	21%	21%	171	141	21%		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—						
Xalkori	137	155	(11)%	(15)%	42	63	(34)%		96	91	5%	(2)%	40	44	(10)%	(20)%	15	14	8%	3%	41	33	25%	20%						
Inlyta	81	88	(7)%	(10)%	33	34	(3)%		48	54	(10)%	(14)%	13	18	(30)%	(37)%	21	22	(4)%	(8)%	15	14	6%	7%						
Bosulfif	77	59	32%	33%	52	39	33%		25	19	29%	19%	13	11	17%	5%	11	8	38%	33%	2	1	77%	68%						
All other Oncology	118	73	62%	54%	41	11	—		77	62	24%	15%	38	32	21%	9%	9	7	27%	23%	30	23	28%	22%						
Inflammation & Immunology (I&I)^(b)	\$ 1,222	\$ 1,087	12%	9%	\$ 485	\$ 341	42%		\$ 737	\$ 745	(1)%	(6)%	\$ 394	\$ 417	(6)%	(16)%	\$ 141	\$ 138	3%	—	\$ 202	\$ 190	6%	11%						
Enbrel (Outside the U.S. and Canada)	551	617	(11)%	(15)%	—	—	—		551	617	(11)%	(15)%	293	350	(16)%	(25)%	92	99	(7)%	(10)%	166	168	(1)%	3%						
Xeljanz	463	336	38%	31%	379	290	31%		84	47	79%	77%	26	6	—	—	31	23	36%	32%	26	17	52%	64%						
Infectra/Remsimia	158	94	68%	58%	63	23	—		95	71	34%	21%	80	64	25%	12%	6	2	—	—	9	5	91%	81%						
Eucrisa	39	9	—	—	39	9	—		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—						
All other I&I	11	31	(64)%	(64)%	3	20	(82)%		7	11	(33)%	(34)%	(5)	(3)	(96)%	(82)%	13	14	(8)%	(11)%	—	—	—	—						
Rare Disease	\$ 571	\$ 562	2%	(3)%	\$ 154	\$ 168	(8)%		\$ 418	\$ 394	6%	(1)%	\$ 219	\$ 219	—	(11)%	\$ 100	\$ 97	4%	—	\$ 98	\$ 78	25%	28%						
BeneFIX	141	153	(8)%	(11)%	58	69	(16)%		83	84	(1)%	(7)%	43	47	(8)%	(18)%	22	24	(10)%	(13)%	18	13	41%	44%						
Genotropin	140	135	4%	(1)%	29	26	12%		111	109	2%	(4)%	45	43	5%	(6)%	43	41	6%	2%	23	25	(10)%	(9)%						
Refacto AF/Xyntha	141	139	1%	(4)%	24	31	(24)%		117	108	8%	2%	66	73	(9)%	(19)%	13	14	(4)%	(7)%	37	21	75%	76%						
Somavert	68	61	11%	5%	27	23	14%		41	38	9%	(1)%	33	30	9%	(3)%	5	9	3%	4%	3	3	7%	7%						
All other Rare Disease	81	74	9%	5%	16	18	(14)%		66	56	17%	12%	32	27	19%	6%	17	13	25%	21%	17	16	7%	13%						
Hospital^(b)	\$ 2,077	\$ 2,124	(2)%	(5)%	\$ 829	\$ 1,012	(18)%		\$ 1,248	\$ 1,112	12%	6%	\$ 268	\$ 254	6%	(5)%	\$ 217	\$ 126	(4)%	(8)%	\$ 763	\$ 631	21%	16%						
Sulperazon	150	110	37%	27%	—	—	—		150	110	37%	27%	—	—	—	—	3	3	(12)%	(15)%	148	107	39%	28%						
Medrol ^(b)	123	137	(10)%	(13)%	62	81	(24)%		61	55	10%	(4)%	19	18	9%	(3)%	6	7	(3)%	(7)%	35	31	13%	10%						
Vtend ^(b)	110	101	8%	4%	2	3	(19)%		108	99	9%	4%	10	14	(31)%	(39)%	21	28	(24)%	(27)%	77	57	35%	30%						
Zithromax ^(b)	73	62	17%	10%	2	1	—		70	61	15%	8%	11	9	24%	10%	9	11	(14)%	(17)%	50	41	21%	14%						
EpiPen	95	90	6%	5%	75	72	3%		20	17	19%	13%	—	—	—	—	20	17	19%	13%	—	—	—	—						
Fragmin	74	71	5%	(3)%	4	5	(19)%		71	66	7%	(1)%	38	35	8%	(2)%	18	18	5%	—	14	13	5%	(3)%						
Zyvox ^(b)	66	75	(13)%	(17)%	(3)	9	(134)%		69	66	5%	0%	5	8	(41)%	(47)%	15	17	(11)%	(14)%	49	41	20%	16%						
Tyagcil	63	57	10%	4%	7	9	(28)%		56	48	18%	10%	19	20	(5)%	(15)%	2	2	1%	(4)%	36	27	35%	29%						
Zosyn/Tazocin	58	41	44%	44%	39	37	6%		20	4	—	—	2	—	—	—	1	—	—	—	16	4	—	—						
Precedex	64	67	(5)%	(7)%	38	43	(12)%		26	25	6%	2%	—	—	—	—	15	13	19%	15%	11	12	(8)%	(11)%						
Pfizer CentreOne ^(b)	209	171	22%	20%	120	132	(9)%		89	39	—	—	35	29	22%	18%	3	4	(25)%	(24)%	51	7	—	—						
All other Anti-infectives	308	411	(25)%	(28)%	64	175	(63)%		243	236	3%	(2)%	73	56	30%	16%	28	30	(6)%	(9)%	142	150	(5)%	(7)%						
All other Hospital ^(b)	684	732	(7)%	(8)%	420	446	(6)%		264	286	(8)%	(12)%	56	65	(14)%	(23)%	74	78	(5)%	(8)%	134	143	(7)%	(10)%						
UPJOHN^(b)	\$ 3,147	\$ 3,356	(6)%	(9)%	\$ 1,282	\$ 1,544	(17)%		\$ 1,865	\$ 1,812	3%	(3)%	\$ 280	\$ 336	(17)%	(25)%	\$ 557	\$ 554	1%	(3)%	\$ 1,028	\$ 922	11%	6%						
Lyrca	1,223																													

Pfizer Inc. Revenues -- Recast to Reflect 2019 Commercial Operating Structure**
Third Quarter 2018 and 2017
Unaudited
(millions of dollars)
Quarter-To-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)			
			% of Change				% of Change				% of Change				% of Change		% of Change				% of Change			
	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational
TOTAL REVENUES	\$ 13,298	\$ 13,168	1%	2%	\$ 6,361	\$ 6,534	(3%)		\$ 6,937	\$ 6,634	5%	6%	\$ 2,231	\$ 2,163	3%	2%	\$ 1,640	\$ 1,632	1%	1%	\$ 3,066	\$ 2,839	8%	13%
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	\$ 9,422	\$ 8,968	5%	6%	\$ 4,684	\$ 4,531	3%		\$ 4,738	\$ 4,437	7%	9%	\$ 1,867	\$ 1,743	7%	6%	\$ 1,024	\$ 989	4%	4%	\$ 1,847	\$ 1,705	8%	15%
Internal Medicine^(c)	\$ 2,182	\$ 2,032	7%	9%	\$ 1,107	\$ 1,085	2%		\$ 1,075	\$ 948	13%	16%	\$ 425	\$ 332	28%	27%	\$ 323	\$ 334	(3%)	(3%)	\$ 327	\$ 281	16%	25%
Eliquis alliance revenues and direct sales	870	644	35%	36%	455	352	29%		416	291	43%	44%	254	168	51%	50%	85	69	24%	24%	77	54	42%	51%
Chantix/Champix	261	240	9%	9%	197	180	10%		64	60	6%	7%	19	18	5%	4%	27	31	(13%)	(12%)	18	11	63%	69%
Premarin family	204	238	(15%)	(15%)	191	224	(15%)		12	14	(14%)	(12%)	—	1	(28%)	(29%)	6	7	(14%)	(13%)	6	7	(13%)	(10%)
BMP2	54	79	(32%)	(32%)	54	80	(33%)		—	(1)	*	*	—	(1)	*	*	—	—	—	—	—	—	—	—
Toviaz	67	62	8%	8%	23	19	21%		44	43	2%	3%	17	18	(1%)	(2%)	24	23	5%	5%	3	3	(4%)	12%
Pristiq	52	69	(24%)	(22%)	20	26	(21%)		32	43	(26%)	(23%)	7	7	—	(1%)	11	18	(39%)	(37%)	14	18	(24%)	(17%)
All other Internal Medicine	675	702	(4%)	(1%)	168	204	(18%)		507	497	2%	5%	127	122	5%	4%	170	187	(9%)	(9%)	210	189	11%	21%
Vaccines	\$ 1,845	\$ 1,649	12%	13%	\$ 1,149	\$ 1,012	14%		\$ 695	\$ 637	9%	12%	\$ 229	\$ 207	11%	9%	\$ 103	\$ 103	—	—	\$ 363	\$ 327	11%	17%
Prevnar 13/Prevenar 13	1,660	1,522	9%	10%	1,089	971	12%		571	551	4%	6%	136	139	(2%)	(3%)	94	99	(5%)	(5%)	340	314	9%	14%
FSME/IMMUN-Tico/Vac	57	43	31%	30%	—	—	—		57	43	31%	30%	52	39	33%	32%	—	—	—	—	5	4	17%	14%
Trumenba	61	42	46%	46%	60	42	44%		1	—	*	*	1	—	*	*	—	—	—	—	—	—	—	—
All other Vaccines	67	43	57%	61%	—	—	—		67	43	57%	61%	40	29	39%	37%	9	4	99%	*	18	9	92%	*
Oncology^(d)	\$ 1,840	\$ 1,679	10%	11%	\$ 1,119	\$ 1,095	2%		\$ 720	\$ 584	23%	26%	\$ 371	\$ 305	22%	21%	\$ 148	\$ 90	65%	65%	\$ 201	\$ 190	6%	16%
Ibrance	1,025	878	17%	18%	708	713	(1%)		317	165	93%	98%	194	116	66%	65%	67	10	*	*	57	39	47%	75%
Sutent	248	276	(10%)	(9%)	80	87	(7%)		168	189	(11%)	(9%)	79	86	(8%)	(9%)	30	30	(3%)	(2%)	59	73	(19%)	(13%)
Xtandi alliance revenues	180	150	20%	20%	180	150	20%		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Xalkori	127	146	(13%)	(12%)	34	49	(31%)		93	96	(4%)	(2%)	35	47	(25%)	(26%)	14	14	(3%)	(4%)	44	35	24%	29%
Inlyta	71	84	(15%)	(13%)	27	30	(10%)		44	53	(18%)	(15%)	11	17	(33%)	(34%)	19	21	(9%)	(10%)	14	15	(12%)	(2%)
Bosulfif	69	57	20%	19%	43	38	13%		26	19	33%	33%	14	9	50%	48%	10	9	17%	17%	2	2	22%	26%
All other Oncology	120	89	35%	35%	48	28	69%		72	61	19%	19%	37	29	29%	28%	9	6	44%	44%	26	26	2%	4%
Inflammation & Immunology (I&I)^(e)	\$ 1,184	\$ 1,113	6%	8%	\$ 447	\$ 357	25%		\$ 737	\$ 755	(2%)	—	\$ 406	\$ 422	(4%)	(4%)	\$ 160	\$ 141	13%	14%	\$ 171	\$ 193	(11%)	1%
Embril (Outside the U.S. and Canada)	531	613	(13%)	(11%)	—	—	—		531	613	(13%)	(11%)	298	355	(16%)	(17%)	101	99	2%	3%	133	159	(17%)	(6%)
Xeljanz	432	348	24%	26%	332	291	14%		100	57	76%	84%	30	10	*	*	41	25	67%	69%	29	22	31%	50%
Infectra/Remsimba	166	112	48%	48%	71	34	*		95	78	22%	22%	79	64	24%	23%	6	4	74%	78%	10	11	(13%)	(6%)
Eucrisa	40	15	*	*	40	15	*		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All other I&I	14	23	(40%)	(41%)	4	17	(76%)		10	7	54%	51%	(1)	(7)	86%	84%	11	14	(19%)	(19%)	—	—	—	—
Rare Disease	\$ 531	\$ 569	(7%)	(5%)	\$ 157	\$ 162	(3%)		\$ 374	\$ 407	(8%)	(6%)	\$ 201	\$ 233	(14%)	(15%)	\$ 90	\$ 96	(6%)	(6%)	\$ 83	\$ 78	6%	17%
BeneFIX	132	151	(13%)	(12%)	57	64	(10%)		74	87	(15%)	(13%)	36	51	(29%)	(30%)	21	24	(14%)	(13%)	18	13	39%	53%
Genotropin	143	136	5%	6%	35	26	37%		108	111	(2%)	(1%)	45	46	(1%)	(2%)	39	41	(4%)	(4%)	24	24	(1%)	8%
Refacio AF/Xyntha	117	140	(16%)	(15%)	27	29	(8%)		90	110	(18%)	(16%)	57	76	(25%)	(26%)	10	12	(15%)	(13%)	23	21	7%	18%
Somavert	64	65	(2%)	(2%)	23	24	(3%)		41	41	(1%)	(1%)	33	32	1%	—	5	5	—	—	3	4	(17%)	(6%)
All other Rare Disease	74	77	(3%)	(1%)	14	19	(28%)		61	58	5%	8%	30	28	10%	9%	15	14	8%	8%	15	16	(5%)	7%
Hospital^(f)	\$ 1,841	\$ 1,926	(4%)	(4%)	\$ 705	\$ 820	(14%)		\$ 1,136	\$ 1,106	3%	4%	\$ 234	\$ 244	(4%)	(5%)	\$ 200	\$ 225	(11%)	(10%)	\$ 702	\$ 637	10%	12%
Sulperazon	145	114	28%	26%	—	—	—		145	114	28%	26%	—	—	—	—	2	3	(19%)	(19%)	143	111	29%	28%
Medrol ^(g)	110	123	(11%)	(10%)	55	68	(20%)		55	55	1%	1%	18	18	(1%)	(2%)	6	6	4%	5%	31	31	1%	3%
Vtend ^(g)	87	97	(11%)	(9%)	3	3	16%		83	94	(11%)	(9%)	8	12	(34%)	(34%)	18	25	(26%)	(26%)	57	57	—	3%
Fragmin	76	79	(4%)	(4%)	4	6	(32%)		72	73	(2%)	(1%)	35	36	(4%)	(4%)	18	20	(11%)	(10%)	19	16	15%	16%
Zithromax ^(g)	54	62	(12%)	(13%)	—	3	*		54	59	(8%)	(8%)	9	9	4%	2%	8	9	(13%)	(13%)	38	42	(10%)	(10%)
EpiPen	68	82	(18%)	(17%)	55	57	(3%)		13	26	(49%)	(49%)	—	—	—	—	13	26	(49%)	(49%)	—	—	—	—
Tyagcil	60	60	—	1%	6	9	(31%)		54	52	5%	6%	15	20	(26%)	(27%)	1	2	(24%)	(25%)	38	30	27%	30%
Zyvox ^(g)	50	68	(26%)	(26%)	(3)	6	(156%)		53	62	(13%)	(13%)	3	6	(51%)	(51%)	14	15	(11%)	(11%)	37	41	(9%)	(9%)
Zosyn/Tazocin	56	47	19%	22%	35	36	(2%)		21	11	86%	98%	1	1	36%	32%	1	1	16%	17%	19	10	95%	*
Precedex	47	51	(6%)	(6%)	17	22	(21%)		30	29	5%	6%	—	—	—	—	18	15	24%	24%	12	14	(15%)	(13%)
Pfizer CentreOne ^(h)	159	161	(1%)	(1%)	81	128	(37%)		78	33	*	*	31	21	49%	50%	5	5	(5%)	(5%)	42	7	*	*
All other Anti-infectives	307	337	(9%)	(7%)	71	107	(34%)		237	230	3%	6%	66	61	7%	6%	29	27	7%	7%	142	142	—	5%
All other Hospital ⁽ⁱ⁾	621	646	(4%)	(3%)	381	377	1%		240	270	(11%)	(10%)	49	61	(19%)	(21%)	66	71	(7%)	(4%)	125	137	(9%)	(8%)
UPJOHN^(j)	\$ 3,036	\$ 3,371	(10%)	(10%)	\$ 1,231	\$ 1,553	(21%)		\$ 1,805	\$ 1,818	(1%)	—	\$ 266	\$ 326	(18%)	(19%)	\$ 537	\$ 567	(5%)	(6%)	\$ 1,001	\$ 925	8%	10%
Lyrica	1,213	1,285	(6%)	(5%)	875	877	—		338	408	(17%)	(17%)	62	107	(42%)	(43%)	205	223	(8%)	(8%)	71	78	(9%)	(5%)
Lipitor	507	491	3%	3%	25	60	(58%)		482	431	12%	11%	43	44	(2%)	(3%)	54	55	(2%)	(2%)	385	333	16%	15%
Norvasc	248	226	10%	10%	9	9	(2%)		239	217	10%	11%	16	16	3%	1%	45	50	(10%)	(10%)	178	151	18%	19%
Viagra	137	308	(55%)	(55%)	32	198	(84%)		105	111	(5%)	(3%)	11	11	(4%)	(5%)	18	17	6%	8%	76	82	(7%)	(5%)
Celebrex	188	212	(11%)	(11%)	16	61	(73%)		171	150	14%	14%	7	7	(8%)	(10%)	79	68	16%	15%	86	75	15%	15%
Xalatan/Xalacom	76	83	(8%)	(7%)	4	4																		

Pfizer Inc. Revenues -- Recast to Reflect 2019 Commercial Operating Structure**
Fourth Quarter 2018 and 2017
Unaudited
(millions of dollars)
Quarter-To-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)			
			% of Change				% of Change				% of Change				% of Change				% of Change					
	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational
TOTAL REVENUES	\$ 13,976	\$ 13,703	2%	5%	\$ 6,468	\$ 6,510	(1)%		\$ 7,508	\$ 7,192	4%	10%	\$ 2,459	\$ 2,200	12%	15%	\$ 1,755	\$ 1,815	(3)%	(1)%	\$ 3,294	\$ 3,178	4%	13%
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(a)	\$ 9,820	\$ 9,329	5%	8%	\$ 4,661	\$ 4,553	2%		\$ 5,160	\$ 4,776	8%	14%	\$ 2,031	\$ 1,736	17%	20%	\$ 1,087	\$ 1,081	1%	3%	\$ 2,041	\$ 1,959	4%	15%
Internal Medicine^(a)	\$ 2,340	\$ 2,232	5%	8%	\$ 1,187	\$ 1,102	8%		\$ 1,153	\$ 1,129	2%	7%	\$ 461	\$ 440	5%	8%	\$ 350	\$ 351	--	2%	\$ 342	\$ 339	1%	13%
Eliquis alliance revenues and direct sales	910	710	28%	31%	478	377	27%		432	333	30%	35%	256	195	31%	35%	93	77	22%	24%	83	61	35%	49%
Chantix/Champix	296	271	9%	10%	236	200	18%		59	71	(16)%	(12)%	23	23	(1)%	2%	26	35	(24)%	(22)%	10	13	(20)%	(10)%
Premarin family	227	266	(15)%	(14)%	214	251	(15)%		13	15	(11)%	(7)%	--	1	(12)%	(10)%	6	7	(6)%	(2)%	6	8	(16)%	(11)%
BMP2	72	64	14%	14%	71	64	12%		1	--	--	--	--	--	--	--	--	--	--	--	1	--	--	--
Toviaz	74	70	5%	7%	25	22	15%		49	48	--	4%	19	19	(2)%	1%	27	26	3%	5%	3	3	(13)%	11%
Pristiq	50	73	(32)%	(29)%	14	28	(51)%		36	45	(19)%	(15)%	9	8	14%	17%	11	19	(40)%	(37)%	15	18	(13)%	(5)%
All other Internal Medicine	711	778	(9)%	(4)%	148	160	(8)%		564	618	(9)%	(3)%	154	194	(21)%	(19)%	186	188	(1)%	--	224	236	(5)%	7%
Vaccines	\$ 1,624	\$ 1,617	--	3%	\$ 780	\$ 789	(1)%		\$ 844	\$ 828	2%	7%	\$ 307	\$ 291	6%	8%	\$ 102	\$ 135	(24)%	(22)%	\$ 434	\$ 403	8%	16%
Prevnar 13/Prevnar 13	1,512	1,533	(1)%	1%	763	780	(2)%		749	753	(1)%	5%	236	228	4%	6%	98	130	(25)%	(23)%	415	395	5%	13%
FSME/IMMUN-TicoVac	22	15	44%	48%	--	--	--		22	15	44%	48%	19	13	38%	42%	--	--	--	--	3	2	--	--
Trumenba	21	9	--	--	17	9	95%		4	--	--	--	3	--	--	--	--	--	--	--	1	--	--	--
All other Vaccines	69	60	16%	24%	--	--	--		69	60	16%	24%	50	49	1%	4%	5	5	(3)%	5%	15	6	--	--
Oncology^(a)	\$ 1,984	\$ 1,572	26%	29%	\$ 1,225	\$ 1,221	--		\$ 759	\$ 351	--	--	\$ 408	\$ 59	--	--	\$ 166	\$ 97	71%	73%	\$ 185	\$ 195	(5)%	12%
Ibrance	1,133	716	58%	62%	743	777	(4)%		389	(61)	--	--	242	(123)	--	--	79	12	--	--	69	49	40%	77%
Sutent	264	276	(5)%	--	96	96	(1)%		168	180	(7)%	--	83	84	(2)%	1%	30	32	(5)%	(3)%	55	64	(14)%	(1)%
Xtandi alliance revenues	189	168	12%	12%	189	168	12%		--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Xalkori	107	152	(30)%	(27)%	40	53	(25)%		67	99	(32)%	(29)%	33	44	(26)%	(24)%	15	15	(3)%	(2)%	19	39	(51)%	(45)%
Inlyta	72	83	(14)%	(10)%	31	31	1%		40	52	(23)%	(17)%	11	16	(32)%	(30)%	20	22	(9)%	(8)%	10	14	(33)%	(14)%
Bosulfif	89	70	27%	28%	61	46	31%		28	24	20%	22%	15	13	17%	20%	11	9	21%	22%	2	2	26%	35%
All other Oncology	131	106	24%	26%	65	48	35%		66	57	14%	19%	24	24	2%	5%	11	7	74%	76%	30	27	11%	19%
Inflammation & Immunology (I&I)^(a)	\$ 1,301	\$ 1,238	5%	9%	\$ 546	\$ 435	26%		\$ 754	\$ 803	(6)%	1%	\$ 394	\$ 448	(12)%	(9)%	\$ 142	\$ 150	(5)%	(3)%	\$ 218	\$ 205	6%	25%
Embril (Outside the U.S. and Canada)	524	634	(17)%	(11)%	--	--	--		524	634	(17)%	(11)%	271	357	(24)%	(22)%	75	102	(27)%	(25)%	177	175	1%	18%
Xeljanz	553	410	35%	37%	429	340	26%		124	70	75%	89%	46	18	--	--	47	30	59%	63%	31	23	33%	64%
Infectra/Remsimia	173	135	28%	31%	70	44	58%		103	91	14%	18%	84	79	6%	10%	8	4	94%	--	10	7	49%	64%
Eucrisa	43	34	25%	25%	43	34	24%		--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
All other I&I	9	25	(65)%	(66)%	5	17	(73)%		4	8	(50)%	(52)%	(7)	(6)	(19)%	(22)%	11	14	(20)%	(20)%	--	--	--	--
Rare Disease	\$ 561	\$ 603	(7)%	(3)%	\$ 170	\$ 176	(4)%		\$ 391	\$ 427	(8)%	(3)%	\$ 207	\$ 232	(11)%	(8)%	\$ 92	\$ 101	(9)%	(7)%	\$ 92	\$ 94	(2)%	15%
Genotropin	142	157	(9)%	(6)%	34	42	(18)%		108	115	(6)%	(1)%	46	48	(4)%	(2)%	39	42	(6)%	(5)%	23	26	(10)%	7%
BeneFIX	134	150	(11)%	(8)%	62	62	(1)%		73	88	(18)%	(13)%	34	46	(27)%	(24)%	18	24	(23)%	(21)%	21	19	10%	26%
Refacto AF/Xyntha	125	142	(12)%	(8)%	28	26	6%		97	116	(16)%	(11)%	58	74	(22)%	(19)%	11	14	(20)%	(15)%	28	29	(1)%	14%
Somavert	73	71	2%	4%	29	28	3%		44	44	1%	5%	34	34	1%	3%	6	5	13%	16%	4	4	(13)%	6%
All other Rare Disease	86	82	6%	12%	17	18	(3)%		69	64	8%	16%	36	31	16%	19%	17	17	4%	6%	16	16	(1)%	19%
Hospital^(a)	\$ 2,011	\$ 2,068	(3)%	--	\$ 753	\$ 830	(9)%		\$ 1,258	\$ 1,237	2%	6%	\$ 254	\$ 267	(5)%	(2)%	\$ 235	\$ 247	(5)%	(2)%	\$ 770	\$ 723	6%	12%
Suplerazon	149	126	18%	24%	--	--	--		149	126	18%	24%	--	--	--	--	2	3	(23)%	(23)%	147	123	20%	25%
Medrol ^(a)	124	146	(15)%	(13)%	66	87	(25)%		59	59	(1)%	3%	18	19	(4)%	(2)%	8	7	12%	16%	33	33	(1)%	4%
Vtend ^(a)	98	115	(15)%	(10)%	3	3	(18)%		95	112	(15)%	(9)%	8	13	(39)%	(38)%	20	26	(21)%	(20)%	67	74	(9)%	(1)%
EpiPen	88	37	--	--	67	22	--		21	15	38%	44%	--	--	--	--	21	15	38%	44%	--	--	--	--
Fragmin	72	85	(15)%	(12)%	2	6	(64)%		70	80	(12)%	(8)%	33	41	(20)%	(17)%	20	22	(6)%	(2)%	17	17	1%	6%
Zithromax ^(a)	75	69	9%	12%	2	(2)	--		73	71	3%	6%	13	13	(1)%	1%	11	13	(20)%	(19)%	49	44	11%	15%
Tygalil	62	69	(9)%	(5)%	6	6	(4)%		56	62	(10)%	(5)%	13	22	(40)%	(38)%	1	1	(9)%	(8)%	42	39	7%	13%
Zyvox ^(a)	52	61	(15)%	(13)%	(2)	(9)	(74)%		54	71	(23)%	(21)%	2	5	(65)%	(65)%	15	17	(14)%	(13)%	38	49	(22)%	(19)%
Zosyn/Tazocin	54	70	(22)%	(20)%	34	53	(36)%		20	16	22%	32%	--	1	(64)%	(63)%	1	1	41%	42%	19	15	26%	37%
Precedex	47	61	(23)%	(20)%	15	37	(59)%		32	24	34%	40%	--	--	--	--	18	14	34%	37%	14	10	33%	44%
Pfizer CentreOne ^(a)	215	192	12%	14%	113	140	(19)%		102	52	96%	--	48	29	66%	71%	5	5	6%	6%	50	19	--	--
All other Anti-infectives	309	363	(15)%	(11)%	64	95	(33)%		245	267	(8)%	(3)%	71	69	3%	6%	28	29	(3)%	(2)%	145	169	(14)%	(7)%
All other Hospital ^(a)	665	673	(1)%	1%	384	392	(2)%		281	281	--	4%	48	55	(14)%	(12)%	84	94	(11)%	(6)%	149	132	13%	18%
UPJOHN^(a)	\$ 3,182	\$ 3,424	(7)%	(5)%	\$ 1,288	\$ 1,445	(11)%		\$ 1,894	\$ 1,979	(4)%	(1)%	\$ 289	\$ 333	(13)%	(11)%	\$ 581	\$ 651	(11)%	(10)%	\$ 1,024	\$ 995	3%	9%
Lyrica	1,320	1,254	5%	6%	951	861	10%		369	393	(6)%	(4)%	67	89	(25)%	(23)%	221	212	4%	5%	80	92	(13)%	(6)%
Lipitor	524	574	(9)%	(5)%	24	35	(31)%		499	539	(7)%	(4)%	50	55	(9)%	(6)%	59	121	(52)%	(51)%	390	362	8%	13%
Norvasc	251	248	1%	6%	9	10	(8)%		242	238	2%	6%	16	18	(9)%	(6)%	43	60	(27)%	(27)%	183	161	14%	20%
Celebrex	192	210	(9)%	(7)%	15	47	(68)%		177	163	8%	11%	8	8	--	3%	91	72	26%	27%	78	83	(6)%	(2)%
Viagra	127	209	(39)%	(37)%	21	102	(80)%		106	107	(1)%	4%	10	12	(16)%	(13)%	18	19	(4)%	--	77	75	2%	8%
Xalatan/Xalacom	85	94	(9)%	(6)%	4	5	(11)%		81	89	(9)%	(5)%	17	24	(13)%	(11)%	31	3						

PFIZER INC.
FOOTNOTES FOR RECAST 2018 and 2017 REVENUES

-
- (a) Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are described in footnotes (m) to (o) below, respectively.
-
- (b) The Pfizer Biopharmaceutical Group encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Hospital. The new Hospital business unit commercializes our global portfolio of sterile injectable and anti-infective medicines, and also includes Pfizer CentreOne^(h).
-
- (c) We reclassified certain products from the Legacy Established Products (LEP) category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2017 and 2018 product revenues to Pfizer's current commercial operating structure beginning in first-quarter 2019.
-
- (d) We performed certain reclassifications in the All other Oncology category to conform 2017 and 2018 product revenues to Pfizer's current commercial operating structure beginning in first-quarter 2019.
-
- (e) We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation & Immunology category to conform 2017 and 2018 product revenues to Pfizer's current commercial operating structure beginning in first-quarter 2019.
-
- (f) Hospital is a new business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy Sterile Injectables Pharmaceuticals (SIP) category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2017 and 2018 product revenues to Pfizer's current commercial operating structure beginning in first-quarter 2019. Hospital also includes Pfizer CentreOne(h).
-
- (g) Revenues for Medrol, Vfend, Zithromax and Zyvox may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.
-
- (h) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In fourth-quarter 2017, we sold our equity share in Hisun Pfizer. As a result, effective in first-quarter 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.
-
- (i) All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in "All other Anti-infectives".
-
- (j) Pfizer's Upjohn business encompasses off-patent branded and generic established medicines that includes 20 of our off-patent solid oral dose legacy brands including Lyrica, Lipitor, Norvasc, Viagra and Celebrex, as well as certain generic medicines.
-
- (k) Pfizer's Consumer Healthcare business is an over-the-counter medicines business, which we announced in December 2018 will be contributed to, and combined with, GSK's consumer healthcare business to form a new consumer healthcare joint venture, of which we will own 32%, subject to customary closing conditions including GSK shareholder approval and required regulatory approvals.
-
- (l) Reflects revenues from Hospira Infusion Systems (HIS) through February 2, 2017. On February 3, 2017, Pfizer completed the sale of HIS to ICU Medical. Therefore, revenues for first-quarter and full-year 2017 reflect approximately one month of legacy HIS domestic operations and approximately two months of legacy HIS international operations. There were no revenues recorded in any period following the completion of the sale.
-
- (m) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.
-
- (n) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
-
- (o) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
-